Literature DB >> 15615924

Sonographic and Doppler imaging in the diagnosis and treatment of gestational trophoblastic disease: a 12-year experience.

Qi Zhou1, Xiao-Ying Lei, Qing Xie, Jim D Cardoza.   

Abstract

OBJECTIVE: To evaluate the clinical utility of sonography with Doppler examination in the diagnosis and treatment of gestational trophoblastic disease (GTD).
METHODS: A retrospective analysis of 355 cases of GTD seen over a 12-year period in 2 large university referral hospitals in China was performed. Clinical appearances, sonographic findings, Doppler waveforms, and patient outcomes were reviewed. Sonographic and Doppler examinations were performed to diagnose the presence of molar tissue, detect invasive disease, assess disease recurrence, and monitor the efficacy of chemotherapy. Doppler waveforms of 13 patients with normal early pregnancies were also examined for comparison.
RESULTS: Of the 355 patients with GTD, 106 had a classic hydatidiform mole (CHM), 33 had a partial hydatidiform mole (PHM), 184 had an invasive hydatidiform mole (IHM), and 32 had choriocarcinoma. Sonography showed abnormal molar tissue confined to the endometrial cavity in all cases of CHM. In cases of IHM and choriocarcinoma, soft tissue invasion and cystic vascular spaces within the myometrium were shown. Cases of PHM had a thickened, hydropic placenta with a concomitant fetus. Doppler waveforms showed resistive indices of 0.55 (SD, 0.06) for CHM, 0.56 (SD, 0.04) for PHM, 0.28 (SD, 0.06) for IHM, 0.25 (SD, 0.05) for choriocarcinoma, and 0.66 (SD, 0.04) for normal pregnancies. The abnormal sonographic and Doppler findings in invasive disease resolved when chemotherapy was successful.
CONCLUSIONS: Sonography and Doppler imaging were helpful in diagnosing GTD, in determining whether invasive disease was present, in detecting recurrence of disease, and in following the effectiveness of chemotherapy.

Entities:  

Mesh:

Year:  2005        PMID: 15615924     DOI: 10.7863/jum.2005.24.1.15

Source DB:  PubMed          Journal:  J Ultrasound Med        ISSN: 0278-4297            Impact factor:   2.153


  9 in total

Review 1.  Imaging of perfusion using ultrasound.

Authors:  David Cosgrove; Nathalie Lassau
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-08       Impact factor: 9.236

2.  Oncologic Angiogenesis Imaging in the clinic---how and why.

Authors:  Karen A Kurdziel; Liza Lindenberg; Peter L Choyke
Journal:  Imaging Med       Date:  2011-09

3.  Missing choriocarcinoma may be easy but not suspecting it in a high-risk case can be potentially fatal.

Authors:  Papa Dasari
Journal:  BMJ Case Rep       Date:  2015-04-16

Review 4.  Gestational trophoblastic disease: a multimodality imaging approach with impact on diagnosis and management.

Authors:  Sunita Dhanda; Subhash Ramani; Meenkashi Thakur
Journal:  Radiol Res Pract       Date:  2014-07-13

Review 5.  Clinical and radiological correlations in patients with gestational trophoblastic disease.

Authors:  Lana de Lourdes Aguiar Lima; Raphael Câmara Medeiros Parente; Izildinha Maestá; Joffre Amim Junior; Jorge Fonte de Rezende Filho; Carlos Antonio Barbosa Montenegro; Antônio Braga
Journal:  Radiol Bras       Date:  2016 Jul-Aug

6.  Fetal environment.

Authors:  Arun Kinare
Journal:  Indian J Radiol Imaging       Date:  2008-11

7.  Characteristics of Three-Dimensional Power Doppler in Gestational Trophoblastic Disease.

Authors:  Wei Wang; Xueye Tian; Ting Zhang; Yanyan Wang; Zhen Han; Ruifang An
Journal:  Dis Markers       Date:  2015-07-16       Impact factor: 3.434

Review 8.  Is Doppler ultrasound useful for evaluating gestational trophoblastic disease?

Authors:  Lawrence H Lin; Lisandra S Bernardes; Eliane A Hase; Koji Fushida; Rossana P V Francisco
Journal:  Clinics (Sao Paulo)       Date:  2015-12       Impact factor: 2.365

9.  Angiogenin and MMP-2 as potential biomarkers in the differential diagnosis of gestational trophoblastic diseases.

Authors:  Dan Weng; Tao Han; Jin Dong; Ming Zhang; Yang Mi; Yiping He; Xiaojuan Li; Xiaoming Zhu
Journal:  Medicine (Baltimore)       Date:  2022-02-04       Impact factor: 1.889

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.